Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
M Sue KirkmanMark TripputiHeidi Krause-SteinraufIonut BebuHiba AbouAssiHenry BurchElizabeth Duran-ValdezHermes FlorezW Timothy GarveyDaniel S HsiaMaamoun SalamPradipta R Raynull nullPublished in: Diabetes care (2024)
Among participants treated with common second-line drug classes for type 2 diabetes, the liraglutide group had the lowest and glimepiride the highest risk of reaching a composite outcome encompassing glycemic deterioration, weight gain, and hypoglycemia. These findings may inform decision-making regarding type 2 diabetes therapy.
Keyphrases
- glycemic control
- type diabetes
- weight gain
- body weight
- blood glucose
- weight loss
- decision making
- insulin resistance
- body mass index
- cardiovascular disease
- birth weight
- randomized controlled trial
- double blind
- clinical trial
- open label
- emergency department
- phase iii
- cell therapy
- adverse drug
- newly diagnosed
- electronic health record